| In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies M McDermott, AJ Eustace, S Busschots, L Breen, J Crown, M Clynes, ... Frontiers in oncology 4, 40, 2014 | 330 | 2014 |
| The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells SA Glynn, D O'Sullivan, AJ Eustace, M Clynes, N O'Donovan BMC cancer 8, 1-9, 2008 | 139 | 2008 |
| Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines AJ Eustace, J Crown, M Clynes, N O'Donovan Journal of Translational Medicine 6, 1-11, 2008 | 99 | 2008 |
| HER2-family signalling mechanisms, clinical implications and targeting in breast cancer N Elster, DM Collins, S Toomey, J Crown, AJ Eustace, BT Hennessy Breast cancer research and treatment 149, 5-15, 2015 | 91 | 2015 |
| Metabolomic studies of human lung carcinoma cell lines using in vitro 1H NMR of whole cells and cellular extracts M Gottschalk, G Ivanova, DM Collins, A Eustace, R O'Connor, ... NMR in Biomedicine: An International Journal Devoted to the Development and …, 2008 | 65 | 2008 |
| A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies … N Elster, M Cremona, C Morgan, S Toomey, A Carr, A O’Grady, ... Breast cancer research and treatment 149, 373-383, 2015 | 50 | 2015 |
| Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours BC Browne, AJ Eustace, S Kennedy, NA O’Brien, K Pedersen, ... Breast cancer research and treatment 136, 717-727, 2012 | 49 | 2012 |
| Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours BC Browne, AJ Eustace, S Kennedy, NA O’Brien, K Pedersen, ... Breast cancer research and treatment 136, 717-727, 2012 | 49 | 2012 |
| Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis N Walsh, S Kennedy, AM Larkin, D Tryfonopoulos, AJ Eustace, ... British journal of cancer 102 (7), 1157-1162, 2010 | 48 | 2010 |
| Effects of HER family–targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer DM Collins, SF Madden, N Gaynor, D AlSultan, M Le Gal, AJ Eustace, ... Clinical Cancer Research 27 (3), 807-818, 2021 | 43 | 2021 |
| Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted … S Toomey, AJ Eustace, J Fay, KM Sheehan, A Carr, M Milewska, ... Breast Cancer Research 19, 1-12, 2017 | 40 | 2017 |
| Artificial Neural Networks for Classification in Metabolomic Studies of Whole Cells Using 1H Nuclear Magnetic Resonance DF Brougham, G Ivanova, M Gottschalk, DM Collins, AJ Eustace, ... BioMed Research International 2011, 2011 | 39 | 2011 |
| Large expert-curated database for benchmarking document similarity detection in biomedical literature search P Brown, AC Tan, MA El-Esawi, T Liehr, O Blanck, DP Gladue, ... Database 2019, 2019 | 34 | 2019 |
| Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL AJ Eustace, NT Conlon, MSJ McDermott, BC Browne, P O’Leary, ... Bmc Cancer 18, 1-14, 2018 | 33 | 2018 |
| Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer SP Kennedy, M O’Neill, D Cunningham, PG Morris, S Toomey, ... Oncogene 39 (14), 3028-3040, 2020 | 28 | 2020 |
| Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer DC Collins, S Cocchiglia, P Tibbitts, G Solon, FT Bane, J McBryan, ... Oncogene 34 (4), 525-530, 2015 | 26 | 2015 |
| A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib J O’Shea, M Cremona, C Morgan, M Milewska, F Holmes, V Espina, ... Oncotarget 8 (49), 85120, 2017 | 24 | 2017 |
| Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer A Canonici, AL Browne, MFK Ibrahim, KP Fanning, S Roche, NT Conlon, ... Therapeutic advances in medical oncology 12, 1758835919897546, 2020 | 23 | 2020 |
| Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma T Mahgoub, AJ Eustace, DM Collins, N Walsh, N O'Donovan, J Crown International Journal of Oncology 47 (3), 900-908, 2015 | 22 | 2015 |
| The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells A Canonici, Z Qadir, NT Conlon, DM Collins, NA O’Brien, N Walsh, ... Investigational new drugs 36, 581-589, 2018 | 21 | 2018 |
